A Complete Guide to NDCT Rules, 2019 for Clinical Trials in India

India’s regulatory landscape for clinical trials underwent a major transformation with the introduction of the New Drugs and Clinical Trials (NDCT) Rules, 2019. Implemented by the Central Drugs Standard Control Organization (CDSCO), these rules provide a streamlined, transparent, and well-defined framework for the conduct of clinical trials, ethics approval, safety monitoring, and marketing authorisation of new drugs. This tutorial offers an in-depth overview of the NDCT Rules, helping sponsors, investigators, and regulatory professionals comply effectively with Indian clinical research regulations.

What Are NDCT Rules, 2019?

The NDCT Rules, 2019 replaced the previous patchwork of notifications and guidelines with a unified rule set under the Drugs and Cosmetics Act, 1940. Their goal is to promote ethical research, protect trial participants, and expedite drug development through regulatory clarity and global alignment.

Applicability of NDCT Rules:

• All new drug and investigational new drug applications
• Bioavailability and bioequivalence (BA/BE) studies
• Clinical trials conducted in India
• Ethics committee registration and oversight
• Manufacture or import of investigational products

Classification of Clinical Trials:

Clinical trials under the NDCT Rules are divided into phases similar to international guidelines:

• Phase I: First-in-human studies assessing safety and dosage
• Phase II: Efficacy and side-effect evaluation in patients
• Phase III: Large-scale testing for effectiveness and adverse reactions
• Phase IV: Post-marketing surveillance and risk assessment

Key Stakeholders and Responsibilities:

1. Sponsors: Must submit applications through SUGAM portal and ensure GCP compliance, insurance coverage, compensation, and periodic reporting.
2. Investigators: Conduct the trial per protocol and submit safety and status reports to the sponsor and ethics committee.
3. Ethics Committees: Registered with CDSCO and responsible for protocol approval and ongoing oversight of participant safety.
4. CDSCO: India’s national regulatory authority reviewing, approving, and inspecting trials for compliance.

Submission and Approval Process:

NDCT mandates a streamlined and digitalised approach for trial applications:

• Online application via SUGAM portal
• Timeline of 90 working days for CDSCO to provide approval or rejection (reduced to 30 days for drugs approved outside India)
• Parallel ethics committee approval required
• Permission deemed granted if no communication is received within the specified time

Contents of the Application Dossier:

Applicants must submit the following:

• Clinical trial protocol and synopsis
• Investigator’s brochure
• Informed consent forms (ICF)
• Details of sites and investigators
• Insurance and compensation policies
• BA/BE study data (if applicable)
• Preclinical and clinical data (depending on phase)

Safety Reporting Obligations:

NDCT includes strict timelines and mechanisms for safety monitoring:

• SAE Reporting: Sponsors and investigators must report serious adverse events (SAEs) to CDSCO, ethics committee, and sponsor within 14 days.
• Periodic Safety Update Reports (PSURs): Required for marketed drugs post-trial.
• Compensation for Injury or Death: Compensation guidelines are clearly defined and must be executed within 30 days of final determination.

Ethics Committee (EC) Framework:

Ethics Committees play a pivotal role under NDCT:

• Must be registered with CDSCO
• Mandated to review all trial-related documents before approval
• Oversee safety, informed consent, protocol adherence, and rights of trial subjects
• Subject to audits by CDSCO inspectors

Import and Manufacturing Permissions:

NDCT Rules govern the manufacture and import of investigational new drugs:

• Separate licenses must be obtained for import or manufacture
• Approval based on CMC data and trial design
• Batch records, labeling, and expiry dates must comply with CDSCO standards

Clinical Trial Registry of India (CTRI):

Registration of all clinical trials in the CTRI is mandatory before subject enrollment. This ensures public transparency and trial traceability.

Special Provisions for Orphan and Innovative Drugs:

• Waiver of clinical trials in India if approved in other major countries
• Fast-track approval for orphan drugs and drugs for national health emergencies
• Provision for accelerated approval pathways and conditional approvals

Post-Trial Obligations and Amendments:

• Submission of clinical trial report to CDSCO and EC
• Any protocol changes require formal amendment submissions
• Study termination must be reported within 15 working days with justification

Best Practices for NDCT Compliance:

1. Use GCP-compliant templates from Pharma SOPs for protocol and documentation.
2. Engage with CDSCO early through pre-submission meetings for clarity on regulatory expectations.
3. Ensure all investigators and ECs are fully registered and trained.
4. Conduct mock audits and gap assessments against GMP compliance guidelines.
5. Utilize electronic systems for data capture, documentation, and reporting to minimize delays.

Alignment with Global Regulations:

NDCT Rules, 2019 align closely with EMA, USFDA, and ICH guidelines, supporting multinational clinical development and global regulatory harmonization.

Conclusion:

The NDCT Rules, 2019 represent a significant advancement in India’s clinical trial regulation. By defining clear roles, timelines, and compliance requirements, CDSCO has created a transparent and reliable regulatory pathway for clinical research. Stakeholders in India must align with these expectations to ensure both ethical conduct and efficient trial execution. Trusted platforms such as Stability Studies can aid regulatory teams in maintaining quality, documentation, and protocol fidelity throughout the study lifecycle.